



# Glucocorticoids mobilize macrophages by transcriptionally up-regulating the exopeptidase DPP4

Received for publication, September 9, 2019, and in revised form, January 21, 2020. Published, Papers in Press, January 27, 2020, DOI 10.1074/jbc.RA119.010894

David Diaz-Jimenez<sup>‡§</sup>,  Maria Grazia Petrillo<sup>‡</sup>, Jonathan T. Busada<sup>‡</sup>, Marcela A. Hermoso<sup>§</sup>, and John A. Cidlowski<sup>‡1</sup>

From the <sup>‡</sup>Molecular Endocrinology Group, Signal Transduction Laboratory, NIEHS, National Institutes of Health, Research Triangle Park, North Carolina 27709 and the <sup>§</sup>Laboratory of Innate Immunity, Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, Universidad de Chile, Santiago 8380000, Chile

Edited by Henrik G. Dohlman

Glucocorticoids are potent endogenous anti-inflammatory molecules, and their cognate receptor, glucocorticoid receptor (GR), is expressed in nearly all immune cells. Macrophages are heterogeneous immune cells having a central role in both tissue homeostasis and inflammation and also play a role in the pathogenesis of some inflammatory diseases. Paradoxically, glucocorticoids have only a limited efficacy in controlling the resolution of these macrophage-related diseases. Here, we report that the transcriptomes of monocyte-like THP-1 cells and macrophage-like THP-1 cells (THP1-MΦ) have largely conserved gene expression patterns. In contrast, the differentiation to THP1-MΦ significantly altered the sensitivity of gene transcription to glucocorticoids. Among glucocorticoid-regulated genes, we identified the exopeptidase dipeptidyl peptidase-4 (*DPP4*) as a critical glucocorticoid-responsive gene in THP1-MΦ. We found that GR directly induces *DPP4* gene expression by binding to two glucocorticoid-responsive elements (GREs) within the *DPP4* promoter. Additionally, we show that glucocorticoid-induced *DPP4* expression is blocked by the GR antagonist RU-486 and by GR siRNA transfection and that *DPP4* enzyme activity is reduced by *DPP4* inhibitors. Of note, glucocorticoids highly stimulated macrophage mobility; unexpectedly, *DPP4* mediated the glucocorticoid-induced macrophage migration, and siRNA-mediated knockdowns of GR and *DPP4* blocked dexamethasone-induced THP1-MΦ migration. Moreover, glucocorticoid-induced *DPP4* activation was also observed in proinflammatory M1-polarized murine macrophages, as well as peritoneal macrophages, and was associated with increased macrophage migration. Our results indicate that glucocorticoids directly up-regulate *DPP4* expression and thereby induce migration in macrophages, potentially explain-

ing why glucocorticoid therapy is less effective in controlling macrophage-dominated inflammatory disorders.

Glucocorticoids exert a wide array of systemic and tissue-specific effects, by signaling through the cognate glucocorticoid receptor (GR;<sup>2</sup> *NR3C1*) in numerous tissues and cell types to systematically influence development, homeostasis, metabolism, and inflammation (1). One of the most important effects of both endogenous and exogenous glucocorticoids is immunomodulation, exerted mainly by suppressing transcription of pro-inflammatory genes and/or induction of anti-inflammatory genes (2). Synthetic glucocorticoids are commonly prescribed anti-inflammatory and immunomodulatory agents. Their therapeutic activity is substantial in a wide spectrum of diseases, including acute and chronic inflammation, autoimmune disorders (3), organ transplantation (4), and hematological cancers (5).

Contrary to well-known anti-inflammatory effects of glucocorticoids, there is emerging evidence of pro-inflammatory effects during inflammation (6–8). For example, glucocorticoid signaling in macrophages has been reported to up-regulate the expression of NLRP3 inflammasome component and to enhance the ATP-dependent secretion of cytokines such as TNF $\alpha$  and interleukin-6 (9). These findings suggest that glucocorticoids likely play a dual role regulating the innate and adaptive immune response differentially. These effects may depend on the type of inflammatory stimulus (10) and/or the timing of treatment (11), thus modulating the balance of the cellular state toward a net pro-inflammatory or anti-inflammatory state (7). These macrophage-intrinsic properties may explain why glucocorticoids are less effective in macrophage-mediated diseases (12), such as chronic obstructive pulmonary disease (11), ulcerative colitis (13), systemic lupus erythematosus (14), and rheumatoid arthritis (15).

This work was supported by Intramural Research Program of the NIEHS, National Institutes of Health, Grant 1ZIAES090057. This work was also supported by CONICYT-PFCHA/ Doctorado Nacional/ 2015/ 21150264 and a supplemental predoctoral fellowship of the NIH Research Program (Grant 37432) (to D. D. J.), a postdoctoral research associate (PRAT) fellowship from NIGMS, NIH (Grant 1Fi2GM123974) (to J. T. B.), and FONDECYT Grant 1170648 (to M. A. H.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

This article contains Figs. S1–S7.

The data from microarray (GSE135130) and NanoString (GSE135165) were deposited in a GEO database (GSE).

<sup>1</sup> To whom correspondence should be addressed: NIEHS, National Institutes of Health, P.O. Box 12233, MD F3-07, Research Triangle Park, NC 27709. Tel.: 984-287-3545; Fax: 919-541-1367; E-mail: cidlows1@niehs.nih.gov.

<sup>2</sup> The abbreviations used are: GR, glucocorticoid receptor; THP-1 cell, monocyte-like THP-1 cell; THP1-MΦ, macrophage-like THP-1 cell(s); IPA, Ingenuity Pathway Analysis®; TNF, tumor necrosis factor; *DPP4*, dipeptidyl peptidase-4; GRE, glucocorticoid-responsive element; BMDM, bone marrow-derived macrophage; qPCR, quantitative PCR; qRT-PCR, quantitative RT-PCR; M-CSF, macrophage colony-stimulating factor; BMM, bone marrow monocytes; Dex, dexamethasone; NTC, nontargeting control; FAIRE, formaldehyde-assisted isolation of regulatory elements; CAV-1, caveolin-1; PMA, phorbol 12-myristate 13-acetate; ANOVA, analysis of variance; PM, peritoneal macrophages; FBS, fetal bovine serum.

## Glucocorticoids mobilize macrophages via DPP4

Macrophages are involved in all phases of the inflammatory response, including alarm, mobilization, and resolution phases, and are able to drive either the propagation or resolution of inflammation (12, 16). The ontogeny of macrophages is still not fully understood; however, it is accepted that they can be grouped as tissue-resident macrophages (established independently of hematopoiesis) or infiltrating macrophages derived from circulating monocytes that are established following an inflammatory response (17–19). Thus, macrophages may contribute to the pathophysiology of several diseases, including inflammatory disorders (20, 21), cancer (22), and also states of low-grade inflammation such as obesity (23, 24).

The migratory capacity of macrophages has been studied in tumor-associated macrophages, because they have a critical role in different stages of tumor progression (25). In other inflammatory pathologies, such as multiple sclerosis, differences in activation and polarization of macrophages promote their migratory properties toward chemoattractants (26). This migration is associated with cytoskeleton rearrangements and also has been proposed to depend on the levels and type of integrin expression (26). For example, the expression of the chemokine receptor CXCR4 on mouse and human mature macrophages has been associated with migration toward lymph nodes during murine peritonitis resolution (27). Finally, in human macrophages (differentiated from CD14<sup>+</sup> monocytes), CXCR4 expression and cell motility (showing a longer distance traveled) was induced upon dexamethasone stimulation. However, little attention has been directed to the identification of genes essential for macrophage movement (28).

Dipeptidyl peptidase-4 (DPP4), encoding for a membrane glycoprotein with exopeptidase activity, was recently described as being involved in the inflammatory macrophage profile associated with type 2 diabetes, obesity, and atherosclerosis (29, 30). This protein is multifunctional, with both enzymatic and non-enzymatic activities. The extracellular domain of DPP4 presents the catalytic site, primarily associated with inactivation of incretin hormones, such as glucagon-like peptides 1 and 2, and the gastric inhibitory polypeptide, as well as catalysis of chemokines (CCL2/MIP-1a, CXCL12/SDF-1, and CCL5/Rantes, among others) (31). DPP4 has also binding sites for adenosine deaminase and fibronectin, and their binding is associated with pro-inflammatory responses (32).

DPP4 inhibitors, such as linagliptin and sitagliptin (33–36), are useful for the control of blood glucose in type 2 diabetes patients (33) who do not respond well to metformin (34) and sulfonylureas (35) and patients suffering from the diabetogenic effects of glucocorticoids (36, 37).

In this study, using THP-1 cells, we show that the monocyte-to-macrophage differentiation was associated with both higher GR levels and greater sensitivity to glucocorticoids on macrophage-like THP-1 cells (THP1-MΦ) compared with monocyte-like THP-1 cells. These changes resulted in modifications of the glucocorticoid-dependent macrophage transcriptome. During the monocyte-to-THP1-MΦ differentiation, cells undergo chromatin remodeling, thus enhancing GR accessibility to glucocorticoid-response elements (GREs) within the *DPP4* promoter. Furthermore, we show that *DPP4* is a novel glucocorticoid-responsive gene specifically in human and

mouse macrophages, but not regulated in monocytes. An *in vitro* migration assay using THP1-MΦ and M1 polarized bone marrow-derived macrophages (BMDMs) reveals that glucocorticoids regulate the macrophage movement via a DPP4-dependent process.


### Results

#### *Transcriptome analysis of monocyte-like THP-1 cells and macrophage-like THP-1 cells reveals a high conservation of gene expression between both cell types*

We investigated whether the state of cell differentiation among monocytes and macrophages modifies the gene expression, with profiles of monocyte-like THP-1 cells (THP-1) and macrophage-like THP-1 cells (THP1-MΦ) analyzed by genome-wide microarray (Fig. S1). Regulated genes were evaluated through a Venn diagram (Fig. 1A), which showed that a large number of genes are commonly expressed in THP-1 and THP1-MΦ (6,637 genes, corresponding to 82.4% of the total expressed genes). In contrast, 608 genes were only found in THP-1, whereas 803 were restricted to THP1-MΦ (Fig. 1A). Provocatively, a volcano plot comparing genes expressed in THP1-MΦ with monocyte-like THP-1 cells revealed that the gene NR3C1/GR was highly expressed in THP1-MΦ (Fig. 1B). These data were validated by qRT-PCR and Western blotting showing a 6-fold increase in the *GR* mRNA and a 3-fold increase in GR protein in THP1-MΦ compared with undifferentiated monocyte-like THP-1 cells (Fig. 1 (C and D), respectively). Interestingly, this phenomenon also was observed in primary murine BMDMs using M-CSF, where we found an increase in GR mRNA in macrophages post-differentiation from bone marrow monocytes (BMM) (Fig. S2).

#### *Monocyte-to-macrophage differentiation enhances their responsiveness to glucocorticoids in macrophages*

Due to the different expression levels of GR in monocyte-like THP-1 cells and THP1-MΦ, we investigated whether the state of cellular differentiation alters the sensitivity to glucocorticoids. For these experiments, monocyte-like THP-1 cells and THP1-MΦ were treated with dexamethasone (Dex) for 6 h, and total isolated mRNA was subsequently analyzed by a genome-wide microarray. Principal component analysis demonstrated considerable separation between treatment (control *versus* Dex) in both cell types. However, Dex-treated monocyte-like THP-1 cells and THP1-MΦ were dramatically separated, indicating differential glucocorticoid-regulated transcriptomes in these cells (Fig. S3A). To identify unique and common genes regulated by Dex among the cell types, the gene list was sorted by Venn diagram, revealing only 741 genes commonly regulated by Dex in monocyte-like THP-1 cells and THP1-MΦ (Fig. 2A). Moreover, the number of genes uniquely regulated by Dex in THP1-MΦ (4,222 genes) was 7-fold higher with respect to monocyte-like THP-1 cells (529 genes) (Fig. 2A). The most significant genes commonly and uniquely regulated by Dex in monocyte-like THP-1 cells and THP1-MΦ were further plotted on a volcano plot and validated by qRT-PCR (Fig. S3, B–G). To elucidate the significance of these findings in both cell types, gene sets were analyzed by Ingenuity Pathway Analysis® (IPA) software. Provocatively, cellular movement was overrepre-



**Figure 1. The transcriptome of macrophage-like THP-1 cells shows a higher GR expression compared with monocyte-like THP-1 cells.** *A*, Venn diagram summarizing microarray data analysis shows the number of genes commonly expressed by THP-1 cells and MΦ-THP-1 and uniquely expressed in both cell types. *B*, volcano plot showing significantly differentially expressed genes in MΦ-THP-1 versus THP-1. In MΦ-THP-1 GR gene expression (also known as *NR3C1/GRα*) is 4-fold higher than THP-1. Shown is validation by qRT-PCR (*C*) and Western blotting (*D*) of GR expression that is higher in MΦ-THP-1 in comparison to THP-1. Data are mean  $\pm$  S.D. (error bars) and are representative of four independent experiments. \*,  $p < 0.05$ ; two tailed unpaired Student's *t* test.

sented in THP1-MΦ compared with monocyte-like THP-1 cells (Fig. 2*B*). Moreover, cell-mediated immune response, immune cell trafficking, and inflammatory response pathways were enhanced in macrophages compared with monocytes (Fig. 2*B* and Fig. S4), suggesting that THP1-MΦ are more responsive than monocyte-like THP-1 cells to signaling by glucocorticoids.

#### Glucocorticoids enhance macrophage-like THP-1 cell migration


Pathway analysis of the microarray data revealed that cell movement was the top biological function following Dex treatment in both monocyte-like THP-1 cells and THP1-MΦ, although cell movement annotation was more dramatically regulated in Dex-treated THP1-MΦ. The number of genes involved in cell movement and differentially regulated according to IPA was 1,102, 44.3% of which were induced, whereas the remaining 63.7% were inhibited in THP1-MΦ. Heat map analysis of the top 25 genes revealed that the magnitude of Dex-induced gene expression was greater in THP1-MΦ (Fig. 2*C*). Based on these findings, we evaluated how GR could impact THP1-MΦ migratory properties in a cell migration assay based on the Boyden Chamber principle. Spontaneous cell migration assay with cells seeded on the insert and serum as the chemoattractant at the bottom revealed that Dex treatment did not impact the monocyte-like THP-1 cell migratory properties at 6 and 24 h (Fig. 2*D*). However, Dex treatment of THP1-MΦ increased their migratory properties after 24 h (Fig. 2*D*). This effect was blocked by 1-h pretreatment with the GR antagonist, RU486 (Fig. 2*D*). This finding was corroborated by knocking down GR expression via siRNA. THP1-MΦ transfected with siRNA GR had  $\sim$ 75% of GR silenced (Fig. 2*E*) and a significant

reduction in Dex-induced cell migration compared with cells transfected with nontargeting control (NTC) siRNA (Fig. 2*F*). These results suggest that glucocorticoids regulate the migration of macrophage-like THP-1 cells.

#### The DPP4 is a new glucocorticoid-responsive gene regulated in macrophage-like THP-1 cells

Data from our transcriptome analysis suggested that the pathways of cell migration and inflammation were highly regulated by glucocorticoids; thus, to substantiate this finding, we turned to the use of nanostring analysis. Among the 594 genes present in the code set Human Immunology, 194 genes were regulated by Dex, specifically 134 in monocyte-like THP-1 cells and 157 in THP1-MΦ (Fig. 3*A*). The expression pattern of genes related to the immune response sorted through a Venn diagram showed that 97 genes were commonly regulated by Dex in THP-1 and THP1-MΦ (corresponding to 50% of the total regulated genes) (Fig. 3*A*). Additionally, the number of genes regulated exclusively by Dex in THP-1 and THP1-MΦ was 37 and 60, respectively, indicating that almost twice as many genes were differentially regulated by Dex in THP1-MΦ (Fig. 3*A*). Among these genes, *DPP4* was the most up-regulated by glucocorticoids in THP1-MΦ and also was part of the 100 genes mostly induced by microarray (Figs. 2*A* and 3*B*). Interestingly, using a small cohort of RNA samples ( $n = 9$ ) from human monocyte-derived macrophages (38) that were treated with 100 nM dexamethasone for 6 h, we found that glucocorticoids significantly induced the mRNA expression of *DPP4* in 6 of 9 samples analyzed (Fig. S5). Furthermore, *DPP4* was not regulated by glucocorticoids in monocyte-like THP-1 cells (Fig. 3*B*). Glucocorticoid-dependent regulation of *DPP4* was confirmed by qRT-PCR, through a dose-response and time-course analy-






**Figure 2. Glucocorticoids regulate the cell migration of macrophage-like THP-1 cells.** *A*, a Venn diagram, summarizing microarray data analysis, shows the number of genes commonly regulated by Dex in THP-1 cells and in MΦ-THP-1 and uniquely regulated by Dex in both cell types. *B*, top 5 biological functions that are differentially regulated in THP-1 and MΦ-THP-1. *C*, heat map representing the top 25 up-regulated and the top 25 down-regulated genes by glucocorticoids in THP-1 and MΦ-THP-1 associated with the cellular movement pathway. *D*, *in vitro* transwell assay using 10% of FBS as chemoattractant was used to evaluate spontaneous cell migration of THP-1 and MΦ-THP-1 treated with vehicle, 100 nM Dex, 10 μM RU-486, or RU-486 with Dex. The graph shows that Dex treatment induces migration only in MΦ-THP-1, and this phenomenon is reversed by using the GR antagonist RU486. *E*, THP1-MΦ were transfected with NTC or GR siRNAs. 24 h after transfection, GR protein knockdown was evaluated by Western blotting (75% reduction). On the left, a representative immunoblot of GR and β-tubulin expression is shown. Right, densitometry analysis of GR normalized to β-tubulin. *F*, *in vitro* migration assay of THP1-MΦ transfected with NTC or GR siRNAs that have been treated for 24 h with or without 100 nM Dex. The histograms show that GR knockdown abolishes Dex-induced macrophage migration. Cell migration was calculated as percentage relative to vehicle-treated groups. Data are mean ± S.D. (error bars) and are representative of three independent experiments. \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$ ; two-tailed unpaired Student's *t* test (*E*) and one-way ANOVA statistical test with Tukey's multiple-comparison test (*D* and *F*).

sis indicating that high levels of DPP4 mRNA were exclusively up-regulated in THP1-MΦ by 10, 100, and 1000 nM Dex (Fig. 3C) and maximally induced 12 h after Dex treatment (Fig. 3D). Additionally, Dex-induced DPP4 up-regulation was observed at the protein level by Western blotting and flow cytometry,

observing a double immunoreactive band of ~100 and 114 kDa (also induced by 10, 100, and 1,000 nM Dex) (Fig. 3E) and higher fluorescent intensity induced by Dex exclusively in THP1-MΦ (Fig. 3F). Finally, the functionality of GR in DPP4 induction was evaluated through pharmacological and genetic inhibition,



**Figure 3. Glucocorticoids up-regulate *DPP4* mRNA and protein levels in macrophage-like THP-1 cells by GR activation.** *A*, A Venn diagram, summarizing NanoString Immunology code set data analysis, shows the number of genes commonly regulated by Dex in THP-1 cells and MΦ-THP-1 and uniquely regulated by Dex in both cell types. *B*, Heat map of the top 10 up- and down-regulated genes by Dex in THP1-MΦ. *C–F*, glucocorticoid-induced *DPP4* levels are uniquely expressed in THP1-MΦ. Shown are quantitative RT-PCR analyses of *DPP4* mRNA levels in THP-1 and THP1-MΦ in Dex dose-response (*C*) and Dex time course (*D*) experiments. Shown are representative Western blotting (*E*) and flow cytometry (*F*) analysis of *DPP4* protein from THP-1 and THP1-MΦ treated with 100 nM Dex for 24 h. The immunoreactive band is indicated by a red arrow. *G–I*, evaluation of GR participation in *DPP4* up-regulation. Pharmacological inhibition of GR with RU-486 and GR knockdown by siRNA abolish Dex-induced expression of *DPP4* at both mRNA (*G*) and protein (*H* and *I*) levels. Data are mean  $\pm$  S.D. (error bars) and are representative of  $n = 3$  to 6 independent experiments. \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$ ; two-way ANOVA test with Tukey's multiple-comparison test (*C* and *D*) and one-way ANOVA test with Tukey's multiple-comparison test (*G* and *I*).


using a pretreatment with GR antagonist RU-486 and transfection with GR siRNA, respectively. *DPP4* induction by Dex in THP1-MΦ was blocked in the presence of RU486, both at the transcript level (6 h) (Fig. 3*G*) and protein level (24 h) (Fig. 3*H*), and inhibited by GR silencing, at the protein level at 24 h (50% down-regulation with respect to NTC (Fig. 3*I*)).

#### Glucocorticoids regulate *DPP4* expression by binding to GREs in regulatory regions of the *DPP4* gene

Through the determination of nascent RNA levels, we observed that glucocorticoids directly regulated the induction of *DPP4*, with an increase within just 30 min of treatment (Fig. 4*A*), thus indicating that *DPP4* is a direct transcriptional target of the GR. *In silico* analysis of the human *DPP4* gene revealed the presence of numerous putative GREs located in the regulatory region between 1.5 and 6.5 kb upstream of the transcrip-

tion start site, each one with a score higher than 80% in relation to the consensus GRE sequence (Fig. 4*B*). Therefore, monocyte-like THP-1 cells and THP1-MΦ treated with 100 nM Dex or vehicle for 2 h were evaluated by ChIP coupled to real-time PCR (ChIP-qPCR), using anti-GR antibody and IgG isotype as negative control. In THP1-MΦ treated with Dex, an enrichment of GR was observed in GRE  $-4,200/-4,185$  (3.6-fold) and GRE  $-1,782/-1,767$  (3.2-fold) of the regulatory region of *DPP4*, suggesting a direct transcriptional control of the *DPP4* gene by GR (Fig. 4*D*). In Dex-induced monocyte-like THP-1 cells, this effect was not observed (Fig. 4*C*). As a control to evaluate whether there is a differential specificity of GR in the binding to the *DPP4* promoter, we analyzed the recruitment of liganded GR to the GRE located in the promoter region of the glucocorticoid target gene *GILZ*. We observed an enrichment of GR to the GRE of *GILZ* in both monocyte-

## Glucocorticoids mobilize macrophages via DPP4




**Figure 4. Glucocorticoids regulate *DPP4* expression by binding to GREs in the *DPP4* promoter.** *A*, quantitative real-time PCR analysis of *DPP4* nascent mRNA from macrophage-like THP-1 cells (THP1-M $\Phi$ ) that have been treated with 100 nM Dex for the indicated times. Dex treatment stimulates the transcription of a significant amount of *DPP4* nascent mRNA within 30 min following Dex exposure. *B*, schematic representation of a fragment of human *DPP4* gene that highlights two identified GREs located at positions  $-4,200/-4,185$  and  $-1,782/-1,767$  from the transcription start site (TSS). Monocyte-like THP-1 cells (*C*) and THP1-M $\Phi$  (*D*) were treated with or without 100 nM Dex for 2 h to evaluate by ChIP-qPCR the amount of GR bound to *DPP4* GREs exclusively in THP1-M $\Phi$ . GR-ChIP samples were analyzed by quantitative PCR, and the Ct values of each experimental group were analyzed in triplicate, compared with their respective inputs, and normalized to the IgG isotype control. GR recruitment to *DPP4* GREs is expressed as -fold enrichment of Dex- versus vehicle-treated cells. *C* and *D*, ChIP-qPCR of GR-bound GRE located in the promoter region of *GILZ* gene was used as positive control. *E*, chromatin remodeling was measured by FAIRE-qPCR to evaluate GR accessibility to the GREs in the *DPP4* gene and *GILZ* gene (as control) in response to the monocyte-to-macrophage differentiation process. For each GRE, chromatin accessibility was determined and compared with the respective DNA input. Data are mean  $\pm$  S.D. (error bars) and are representative of three independent experiments. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$ . Shown are a one-way ANOVA test with Tukey's multiple-comparison test (*A*) and a two-way ANOVA test with Sidak's multiple-comparison test (*C-E*).

like THP-1 cells and THP1-M $\Phi$  following Dex treatment (6- and 13-fold, respectively, Fig. 4 (*C* and *D*)). These data suggest that chromatin structure reorganization occurs during the monocyte-to-macrophage transition, thus allowing GR binding and serving as the mechanism through which *DPP4* is differentially regulated in monocyte-like THP-1 cells and THP1-M $\Phi$ . To address this question, we evaluated chromatin accessibility using a formaldehyde-assisted isolation of regulatory elements (FAIRE) assay in the same regions of the *DPP4* gene where GR occupied sites according to ChIP-qPCR in macrophages. Upon differentiation and Dex treatment, we observed an increase in DNA accessibility in both regions of the *DPP4* gene flanking GRE  $-4,200/-4,185$  and GRE  $-1,782/-1,767$ , respectively, in THP1-M $\Phi$ , whereas there was limited accessibility of them in monocyte-like THP-1 cells (Fig. 4*E*). As control, DNA accessibility was also observed in the site flanking GRE of the *GILZ* promoter, without differences between THP1-M $\Phi$  and monocyte-like THP-1 cells. The increase in FAIRE enrichment seen at the two GREs of *DPP4* gene suggests that the chromatin remodeling during the monocyte-to-macrophage transition is required for GR to initiate Dex-induced *DPP4* gene transcription.

### Glucocorticoids enhance *DPP4* enzymatic activity in THP1-M $\Phi$ , and this effect is blocked by *DPP4* inhibitors sitagliptin and linagliptin

The effects mediated by *DPP4* in different cell types have been associated with both enzymatic and nonenzymatic functions. Based on this classification (and having shown that liganded GR up-regulates mRNA and protein *DPP4* levels), we evaluated whether glucocorticoids could also modulate the *DPP4* enzymatic activity. For these studies, monocyte-like THP-1 cells and THP1-M $\Phi$  were stimulated with Dex for 24 h or were pretreated with RU-486 or co-stimulated after 3 h with two concentrations of specific *DPP4* inhibitors, sitagliptin and linagliptin. Cell lysates of each experimental condition were evaluated by fluorometric assay, showing no *DPP4* activity from monocyte-like THP-1 cells under evaluated conditions (Fig. 5*A*). Conversely, in THP1-M $\Phi$ , we observed that Dex increased *DPP4* enzymatic activity, and this effect is mediated by GR because it was blocked by RU486 pretreatment (Fig. 5*A*). In addition, using sitagliptin (25 and 50 nM) and linagliptin (1 and 10 nM), we found that both inhibitors completely block *DPP4* enzymatic activity induced by Dex (Fig. 5*A*). Notably, treatment with both *DPP4* inhibitors directly blocked *DPP4* enzymatic



**Figure 5. The cell migration induced by dexamethasone in macrophage-like THP-1 cells is mediated through DPP4 activity.** *A*, the enzymatic activity of DPP4 measured by fluorometric assay and induced by Dex was completely blocked by the DPP4 inhibitors sitagliptin (25 and 50 nM) and linagliptin (1 and 10 nM) in M $\Phi$ -THP-1. *B*, Western blotting for DPP4 showing that both DPP4 inhibitors do not affect the Dex-induced DPP4 protein expression. *C*, THP1-M $\Phi$  were transfected with NTC or DPP4 siRNAs. 24 h after transfection, cells were treated with or without Dex for 24 h, and DPP4 protein knockdown was evaluated by Western blotting (>70% reduction). On the *left*, a representative immunoblot of DPP4 and  $\beta$ -tubulin expression is shown. On the *right*, densitometry analysis of DPP4 normalized to  $\beta$ -tubulin is shown. *D*, Dex-induced THP1-M $\Phi$  migration is mediated by DPP4 expression. An *in vitro* migration assay shows that both pharmacological inhibition of DPP4 enzymatic activity, by linagliptin and sitagliptin, and silencing of DPP4 expression block the spontaneous migration of THP1-M $\Phi$  induced by Dex treatment. *E*, CXCL12-induced THP1-M $\Phi$  migration was blocked by GR and DPP4 knockdowns of cells following Dex treatment. Data are mean  $\pm$  S.D. (error bars) and are representative of 3–4 independent experiments. \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$ ; one-way ANOVA statistical test with Tukey's multiple-comparison test.



## Glucocorticoids mobilize macrophages via DPP4

activity without affecting Dex-induced DPP4 protein expression (Fig. 5B).

### DPP4 promotes macrophage-like THP-1 cell migration

The multifunctionality of DPP4, enzymatic activity to regulate chemokine actions or nonenzymatic via interaction with other proteins, could also regulate, directly or indirectly, macrophage mobility. To investigate this idea, we silenced DPP4 in THP1-M $\Phi$  using siRNA or DPP4 inhibitors, evaluating cell migration behind glucocorticoid effects. Expression of DPP4 induced by Dex was decreased by 80% at the protein level in THP1-M $\Phi$  transfected with siRNA DPP4 with respect to NTC (Fig. 5C). Using this strategy to evaluate GR participation in cell migration, we compared the migratory potential of THP1-M $\Phi$  primed with Dex in the presence of DPP4 inhibitors. Cells were seeded in the insert, and medium with serum was added in the lower chamber as chemoattractant. Interestingly, the Dex-mediated increase in the migratory potential was inhibited in the presence of either 10 nM linagliptin or 50 nM sitagliptin, suggesting that this effect depended on DPP4 catalytic function (Fig. 5D). Finally, NTC and DPP4 siRNA macrophages, primed or unprimed with Dex for 24 h, were used to evaluate DPP4 participation in cell migration. An increase in the migratory potential induced by Dex in the NTC was suppressed by DPP4 knockdown (Fig. 5D), suggesting that DPP4 activity is necessary for enhancing macrophage migration. Interestingly, CXCL12 was able to promote the migration of cells treated with Dex for 24 h, and this effect was inhibited by both GR and DPP4 knockdown (Fig. 5E).

### The induction of the *Dpp4* gene by glucocorticoids is an exclusive mechanism in pro-inflammatory M1 macrophages

Our findings in THP1-M $\Phi$  indicate that glucocorticoids promote cell migration in part by inducing DPP4 expression. To examine whether this is a conserved mechanism, we assessed the effects of Dex treatment on mouse BMM and BMDMs. After inducing macrophage differentiation with M-CSF (M0, unstimulated macrophages), cell cultures were activated by treatment with lipopolysaccharide/interferon- $\gamma$  (M1) or with interleukin-4 (M2). The phenotype of unpolarized (M0) macrophages as well as macrophages polarized to M1 and M2 was evaluated by confocal microscopy, showing the polarization-dependent morphological differences and the “classical” marker CD68 (Fig. 6A). Moreover, qRT-PCR analysis revealed that M1 macrophages exhibited the characteristic up-regulation of *Nos2/iNOS*, *Ccl5/Rantes*, and *Tnf* mRNA, whereas M2 macrophages exhibited increased expression of *Arg1*, *Retnla*, and *Chil3* (Fig. 6B). To assess the impact of macrophage activation on glucocorticoid responsiveness, BMM, M0, M1, and M2 macrophage cultures were treated with 100 nM Dex for 6 h. Quantitative RT-PCR revealed that expression of M1-associated genes *Nos2* and *Tnf* were suppressed 6 h after Dex treatment, whereas expression of M2-associated genes was not affected (Fig. 6B). Interestingly, whereas Dex treatment induced equivalent expression of the classic glucocorticoid target genes *Gilz* in each group and the induction of the chemokine receptor *Cxcr4* in all groups of the macrophage populations, *Dpp4* was exclusively induced only in M1 macrophages

(Fig. 6C and Figs. S6 and S7). Finally, we examined the effects of glucocorticoid treatment on BMDM macrophage migration. For this purpose, M0, M1, and M2 macrophages were treated for 24 h with Dex, and their spontaneous migration was assessed. Consistent with our finding in THP1-M $\Phi$ , we found that Dex treatment enhanced spontaneous migration of M1 macrophages but did not affect the migration of M0 or M2 macrophages (Fig. 6D). Interestingly, M1 macrophages treated with Dex for 24 h and then pretreated or not for 1 h with 50 nM sitagliptin were used to evaluate the CXCL12-induced migration. We observe that the migration of M1 macrophages could also be induced by CXCL12, and this effect was blocked by pretreatment with sitagliptin (Fig. 6E). Finally, we evaluated glucocorticoid-induced effects in peritoneal macrophages that naturally show an ambulatory or motile phenotype. Together with *Gilz* induction, we observed *Dpp4* induction upon Dex treatment (Fig. 6F) and higher cell migration induced by glucocorticoids (Fig. 6G), suggesting that glucocorticoid-induced migration in macrophages is mediated by DPP4.


## Discussion

The glucocorticoid receptor is expressed in almost all immune cells and mediates the actions of both endogenous or exogenous glucocorticoids, acting as potent regulators of inflammation (39). Interestingly, glucocorticoids have complex and different pleiotropic effects on monocytes and macrophages, but their contribution toward systemic anti-inflammatory effects is not yet fully understood. Here, we evaluated whether the process of monocyte-to macrophage differentiation modified glucocorticoid responsiveness. Transcriptome analysis of monocyte-like THP-1 and macrophage-like THP-1 cells revealed a higher GR expression in macrophage-like THP-1 compared with monocyte-like THP-1 cells. In addition, we report the identification of the pro-diabetic and pro-inflammatory exopeptidase DPP4 as a new glucocorticoid-responsive gene exclusively regulated in macrophages. Provocatively, DPP4 promotes the migration of macrophages that is induced by glucocorticoids.

Glucocorticoids suppress inflammation through the induction of potent anti-inflammatory effects and are frequently used to treat chronic inflammatory diseases involving lymphocytes, although they are less effective in suppressing macrophage-mediated diseases (11, 13, 14). Within macrophages, glucocorticoid action depends on the context and the timing, and they also have the capacity to mediate pro-inflammatory activities, such as enhancing leukocyte trafficking and pro-inflammatory cytokine production mainly during the first steps of the immune response (9).

One theory explaining this dual effect on immune cells gene regulation is that glucocorticoids initiate opposing forces simultaneously inducing pro- and anti-inflammatory pathways as a pro-resolutive strategy to quickly recover the cellular and tissue homeostasis (7, 40). The effect of GR activation is highly gene-, cell-, and stimulus-specific, as is evident from our transcriptome data. For example, the inhibition of CSF1 (colony-stimulating factor 1) and its receptor CSF1R could be one possible reason why glucocorticoids alone would not induce the differentiation of monocytes into macrophages.





**Figure 6. Glucocorticoids up-regulate *Dpp4* expression in mouse BMDMs polarized to classically activated profile M1 and peritoneal macrophages promoting migration.** BMM isolated by negative selection and differentiated into BMDM with 100  $\mu\text{g}/\text{ml}$  M-CSF were evaluated by immunofluorescence microscopy. **A**, immunofluorescence staining of *in vitro* cultured mouse M0, M1, and M2 macrophages labeled with the macrophage marker CD68. Scale bar, 20  $\mu\text{m}$ . **B**, gene expression profiles by qRT-PCR of M1 (*Nos2*, *Ccl5*, and *Tnf*) and M2 (*Arg1*, *Retnla*, and *Ym1*) markers at 6 h with 100 nM Dex. **C**, mRNA levels of *Gilz*, *Cxcr4*, and *Dpp4* regulated by glucocorticoids in M0, M1, and M2 macrophages. **D**, *in vitro* migration assay, using 10% FBS as chemoattractant, of M0, M1, and M2 macrophages treated with or without dexamethasone. After 24 h, M1 macrophages show a significant increase in spontaneous migration upon Dex treatment. **E**, the cell migration of primary M1 macrophages induced by CXCL12 is blocked by pharmacological inhibition of DPP4 following dexamethasone treatment. **F**, mRNA levels of *Gilz*, *Cxcr4*, and *Dpp4* regulated by glucocorticoids in mouse PM. **G**, *in vitro* migration assay, using 10% FBS as chemoattractant, of PM treated with or without dexamethasone shows an increase in the migratory potential induced by glucocorticoids. Data are mean  $\pm$  S.D. (error bars) and are representative of 3–5 independent experiments. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$ ; ordinary one-way ANOVA statistical test with Tukey's multiple-comparison test and unpaired two-tailed *t* test.

The process of differentiation of monocytes to macrophages involves major structural and biochemical changes in the cell. However, transcriptome analysis between monocyte-like THP-1 cells and THP1-M $\Phi$  demonstrated a high number of

genes commonly regulated between both cell types. These associations observed could be due to different gene expression levels, rather than *de novo* transcription of uniquely expressed genes, as is the case for GR. Moreover, higher GR levels

## Glucocorticoids mobilize macrophages via DPP4

observed in macrophages could be related to greater sensitivity toward glucocorticoids after differentiation of monocytes.

Genes involved in cell movement, trafficking, and chemotaxis were overrepresented among up- and down-glucocorticoid-regulated genes in THP1-M $\Phi$ , with DPP4 induced and differentially regulated by Dex exclusively in THP1-M $\Phi$  and primary murine polarized M1 macrophages. DPP4, also known as CD26, was originally described as a marker of T cell differentiation and activation (41). This study provides the first evidence that DPP4 expression is directly regulated by glucocorticoids, making it a promising candidate for glucocorticoid effects in human pro-inflammatory macrophages. Additionally, the presence of a highly conserved GRE motif in the position -4,200/-4,185 in humans and mice indicates possible shared mechanisms between species.

The importance of DPP4 for the medical community lies in the approval of the use of its inhibitors for treatment of type 2 diabetes, as monotherapy, or in combination with other oral anti-diabetes drugs (42) and the benefits in decreased risk of major cardiovascular events (43, 44). DPP4 inhibitors have anti-inflammatory effects, playing a critical role in obesity-induced inflammation and insulin resistance limiting macrophage infiltration in chronic inflammatory mouse models and regulating M1/M2 balance by mediating the reversion of one to the other (24). Previously, Zhong *et al.* showed that DPP4 expression was increased during monocyte differentiation into dendritic cells/macrophages and that nonenzymatic DPP4 function was associated with inflammation during obesity (32).

The exopeptidase DPP4 involved in the regulation of the immune system cleaves dipeptides from the N-terminal region of peptides and proteins (with a residue of Ala or Pro in the penultimate position) as well as various chemokines (45). The loss of two amino acids resulting from DPP4 enzymatic action can cause 1) increased or reduced biological peptide/protein activity, 2) increased specificity toward the receptor, 3) ligand inactivation, or 4) generation of receptor antagonists (46). Therefore, as chemokines direct leukocyte migration under homeostasis and inflammation, DPP4 proteolytic processing could have relevant consequences for correct functioning of the immune response. Our findings in macrophage-like THP-1 cells and murine polarized M1 macrophages indicate that glucocorticoids enhance spontaneous and CXCL12-induced migration in part by inducing DPP4 expression.

Noncatalytic DPP4 functions have also been related to adhesion and migration processes and interaction with extracellular matrix proteins (fibronectin and collagen). Moreover, DPP4 inhibitors ameliorate atherosclerosis by preventing monocyte recruitment and chemotaxis via modulation of RAC-1 (21). Additionally, DPP4 in T cells interacts with the chemokine receptor CXCR4 (41), selectively binding the chemokine CXCL12 (45). This binding could promote internalization of the complex DPP4/CXCR4 in the membrane, regulating local and temporal CXCL12 activity (41, 47). Regarding the nonenzymatic activity of DPP4 regulating the macrophage mobility, Hironuma *et al.* (48) have shown that DPP4 inhibitors affect DPP4 and caveolin-1 (CAV-1) interaction, resulting in the suppression of inflammation in mouse and human macrophages. In addition to this, it is well-known that CAV-1 activation of the

GTP-binding protein RAC-1 plays a role in cell migration (49, 50). Thus, DPP4 inhibitors could block the interaction of the DPP4/CXCR4 axis, the activation of CXCR4 by CXCL12, and finally the consequential activation of CAV-1/RAC-1 in the promotion of macrophage mobility. Interestingly, we observed that CXCR4 and CXCL12 genes were enriched in the cell movement and migration pathways by IPA. Our data show that glucocorticoids also increased the expression of these genes in macrophage-like THP-1 cells and primary mouse macrophages and that they could be another downstream regulator of migratory capacity mediated by GR activation.

Finally, enzymatic DPP4 activity induced by Dex was completely blocked by specific DPP4 inhibitors (sitagliptin and linagliptin), suggesting the possibility that synthetic glucocorticoids would present a low efficacy in the resolution of macrophage-induced inflammation. Alternatively, these data also may indicate that glucocorticoids, through DPP4 induction, potentiate the retention and egress of macrophages from inflamed tissues, perhaps contributing to their anti-inflammatory properties of glucocorticoids.

## Materials and methods

### Reagents

Dex and RU486 were purchased from Steraloids, Inc (Newport, RI). Heat-inactivated fetal calf serum and charcoal-stripped heat-inactivated FBS were purchased from Gemini Bio-Products (West Sacramento, CA). RPMI medium, penicillin/streptomycin, HEPES (pH 7.0), and  $\beta$ -mercaptoethanol were purchased from Invitrogen (Thermo Fisher Scientific). Phorbol 12-myristate 13-acetate (PMA) was purchased from Sigma-Aldrich. Recombinant human and mouse CXCL12 were purchased from Biolegend (San Diego, CA). Human anti-GR and anti-DPP-4 antibodies were purchased from Cell Signaling Technology (Danvers, MA). The DPP-4 inhibitors sitagliptin and linagliptin were purchased from Selleckchem (Houston, TX). Dharmafect, NTC, siRNA GR, and siRNA DPP4 (ON-TARGETplus siRNA) were purchased from Horizon/Dharmacon (Lafayette, CO). TaqMan<sup>®</sup> RT-PCR primer probes were purchased from Applied Biosystems (Foster City, CA).

### Mouse colony maintenance

All studies were performed with approval by the NIEHS, National Institutes of Health, animal care and use committee. The mice used for these studies were C57BL/6J purchased from the Jackson Laboratories (Bar Harbor, ME). Mice were maintained in a pathogen-free facility with 12-h day/night cycles. Standard mouse chow and water were provided *ad libitum*.

### Cell culture

The human monocytic cell line THP-1 (ATCC<sup>®</sup>-TIB-202, American Type Culture Collection, Manassas, VA) together with their derived macrophages were maintained in RPMI medium supplemented with 10% heat-inactivated fetal bovine serum, 100 units of penicillin/streptomycin, 25  $\mu$ M HEPES (pH 7.0), and 50  $\mu$ M  $\beta$ -mercaptoethanol (complete medium) at a ratio of  $2.5 \times 10^5$  cells/ml under conditions of humidity at 5%

CO<sub>2</sub> and 37 °C. Monocyte-like THP-1 cells were differentiated into THP1-MΦ. Briefly, monocyte-like THP-1 cells (2 × 10<sup>6</sup> cells/well) were activated with 0.5 μM PMA in serum-free medium supplemented with 25 μM HEPES for 3 h. Subsequently, adherent cells were washed with PBS and cultured first for 24 h with recovery medium without PMA (complete RPMI) and then for another 24 h in RPMI supplemented with 10% charcoal-stripped serum before being treated with dexamethasone. The success of the differentiation protocol was evaluated using phase-contrast microscopy and flow cytometry using a fluorophore-conjugated panel of antibodies against markers of monocyte and macrophage lineages (CD15s-BV510, CD11b-PE-Cy7, and CD11c-BV421) and Cell Tracker and 7-aminoactinomycin D for viability (BD Biosciences) (Fig. S1). Where indicated, cells were pretreated with 1 or 10 μM RU-486 for 1 h prior to the addition of Dex or pretreated with Dex for 3 h prior to the addition of DPP4 inhibitor (linagliptin (1 and 10 nM) or sitagliptin (25 and 50 nM)).

#### Generation of knockout macrophage-like THP-1 cells by siRNA

For siRNA experiments, 3-day macrophage-like THP-1 cells completely differentiated were seeded in 6-well plates at a density of 1 × 10<sup>6</sup> cells/ml and then transfected with 25 nM NTC or with a 25 nM concentration of a mixture of four siRNAs provided as a single reagent of siRNA against GR or against DPP4 (ON-TARGETplus siRNA, Dharmacon) and DharmaFECT-1 in a mixture of Opti-MEM and medium without antibiotic. The transfection reaction was maintained at 37 °C in 5% CO<sub>2</sub> for 24 h. The transfected cells were recovered in complete medium for another 24 h and maintained in charcoal-stripped medium for an additional 24 h prior to adding 100 nM Dex for 6 h for RNA or 24 h for protein analysis. The efficiency of the transfection was evaluated by Western blotting, and cells with GR or DPP4 silencing were used for functional analysis.

#### Analysis of gene expression using microarray, NanoString, and qRT-PCR

Cultures of 1 × 10<sup>6</sup>/ml of monocytes THP-1 and THP1-MΦ were stimulated for 6 h with vehicle or 100 nM Dex for analysis of gene expression by microarray and NanoString (*n* = 3 biological replicates/condition), from 2 to 48 h with 1, 10, 100, and 1000 nM Dex for analysis of time course and dose response and from 0.5 to 6 h with 100 nM Dex for analysis of DPP4 nascent RNA levels (forward, 5'-GCTTCCCTCTAATTGGACTTGGA-3'; probe, 5'-TTGCAGACACCGTGGAAGGTTCTT-3'; reverse, 5'-ACGGTGTATGATGGTGACAAG-3') by qRT-PCR. The data from microarray (GSE135130) and NanoString (GSE135165) were deposited in a GEO database (GSE).

#### Microarray analysis

Following Dex stimulation, cells were collected and lysed for total RNA extraction using a Qiagen RNeasy minikit (Qiagen, Hilden, Germany). Gene expression analysis by microarray was carried out using Agilent whole human genome 4 × 44 multiplex format oligonucleotide arrays (014850) (Agilent Technologies, Santa Clara, CA) following the Agilent one-color microarray-based gene expression analysis protocol. Starting with 500 ng of total RNA, complementary RNA labeled with the

Cy3 probe was synthesized according to the manufacturer's protocol. For each sample, 1.65 μg of Cy3-labeled complementary RNA was fragmented and hybridized for 17 h in a rotating hybridization oven. The oligonucleotide arrays were washed and then scanned with an Agilent scanner. Data were obtained using the Agilent Feature Extraction software (version 12), performing the error modeled, adjusting for additive and multiplicative noise. The resulting data were processed using the OmicSoft Array Studio software (version 7.0) and visualized by principal component analysis. To identify the differentially expressed probes and to determine statistical differences between the means of the groups, an analysis of variance (ANOVA) was used. In addition, we used a multiple-test correction ANOVA and Benjamini–Hochberg with a value of *p* < 0.05 to reduce the number of false positives.

#### NanoString analysis

The analysis of gene expression using the NanoString® platform (NanoString, Seattle, WA) was carried out using the Human Immunology code set (NS\_Immunology\_C2328), which measures 547 endogenous RNAs and 14 housekeeping genes. 50 ng of each total RNA sample was used according to the manufacturer's instructions. RNA expression was quantified in an nCounter Digital Analyzer, and raw counts were generated and normalized with nSolver software (version 3.0). The data were normalized using the manufacturer's positive and negative control probes as well as two housekeeping genes (*HPRT1* and *PPIA*). All samples passed the initial quality assurance/quality control of nSolver, and the replicates were well-correlated (*R* > 0.98). The raw and normalized compiled data (log<sub>2</sub> of counts) were reanalyzed in Partek for statistical analysis (finding 159 probes with an average expression of less than 4 counts that were excluded), with 388 probes finally subjected to ANOVA in the treatment groups with *p* value corrected by false discovery rate post-hoc Benjamini–Hochberg for each comparison group.

#### qRT-PCR analysis

The analysis of the gene expression in dose response and time course using monocyte-like THP-1 cells and THP1-MΦ, human monocyte-derived macrophages (38), murine bone marrow monocytes, bone marrow-derived macrophages, and peritoneal macrophages by qRT-PCR was carried out using 50 ng of total RNA and the One-Step RT-PCR kit (Bio-Rad) together with sets of predesigned and validated TaqMan primer/probes for each analyzed transcript (Applied Biosystems). *NR3C1* (Hs00230813\_m1), *GILZ/TSC22D3* (Hs00608272\_m1), *DPP4* (Hs00897391\_m1), *FKBP5* (Hs01561006\_m1), *PER1* (Hs00242988\_m1), *AREG* (Hs00950669\_m1), *NLRP3* (Hs00918082\_m1), *HSD11B1* (Hs01547870\_m1), *TNF* (Hs99999043\_m1), *CCL2* (Hs00234140\_m1), *HIST1H4C* (Hs00543883\_s1), *CCL20* (Hs00355476\_m1), *CYP19A1* (Hs00903411\_m1), *CD86* (Hs01567026\_m1), *NOX1* (Hs00246589\_m1), *HSD11B2* (Hs00388669\_m1), and *PPIB* (Hs00168719\_m1) human genes and *Nr3c1* (Mm00433832\_m1), *Gilz/Tsc22d3* (Mm00726417\_s1), *Dpp4* (Mm00494549\_m1), *Cxcr4* (Mm01996749\_s1), *Nos2* (Mm00440502\_m1), *Ccl5*



## Glucocorticoids mobilize macrophages via DPP4

(Mm01302427\_m1), *Tnf* (Mm00443258\_m1), *Arg1* (Mm00475988\_m1), *Retnla/Fizz1* (Mm00445109\_m1), *Chil3/Ym1* (Mm00657889\_mH), and *Ppib* (Mm00478295\_m1) for mouse genes. The samples were run in duplicate in the real-time thermocycler model CFX96 from Bio-Rad. The *Ct* values from each transcript were normalized to the housekeeping gene *PPIB* and expressed relative to the level of the transcript in the unstimulated condition. As a positive control of the effect of Dex, the glucocorticoid-responsive genes *FKBP5* and *GILZ* were used. Additionally, the activity of GR and levels of each transcript regulated by Dex were evaluated in the presence or absence of RU-486.

### Analysis of canonical pathways using IPA

The lists of significantly regulated genes were annotated using IPA. Enrichment or overlap of canonical pathways and the top biological functions were determined by IPA, using Fisher's test ( $p < 0.05$ ). Gene networks involved in the inflammatory response, cell movement, and chemotaxis were constructed using the PathDesigner tool of IPA.

### Protein analysis by Western blotting and flow cytometry

Total proteins were extracted in radioimmune precipitation buffer (25 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, and 0.1% SDS) supplemented with an inhibitor mixture of proteases (Roche, Rotkreuz, Switzerland). Equal amounts of protein were loaded and separated in precast Novex 10% Tris-glycine minigels (Thermo Fisher Scientific) and transferred to nitrocellulose membranes under a semidry rapid transfer system (Bio-Rad) and blocked with blocking buffer (LI-COR, Lincoln, NE) for 60 min at room temperature. Subsequently, the membranes were incubated overnight at 4 °C with primary antibodies anti-GR (1:1,000 dilution) and anti-DPP4 (1:1,000 dilution) in 5% skimmed powdered milk in TBS-T and 5% BSA in TBS-T, respectively. Blots were washed and incubated with goat anti-rabbit IRDye680-conjugated secondary antibody (LI-COR) for 1 h at room temperature and visualized with a LI-COR Odyssey Imaging scanner system. The obtained immunoreactivity was normalized to  $\beta$ -actin and/or  $\beta$ -tubulin proteins as a loading control and was expressed relative to the protein level of the unstimulated condition. To determine the expression at the protein level of activation markers in monocyte-like THP-1 cells and THP1-M $\Phi$  by flow cytometry, the cells were stimulated for 24 h with 100 nM Dex, fixed in paraformaldehyde for 10 min at room temperature, and permeabilized according to the surface or intracellular staining evaluated. The immunostaining process was performed using a panel of antibodies (BD Biosciences) conjugated against CD15s-BV510, CD11b-PE-Cy7, and CD26/DPP4-PE and their respective isotypes according to the manufacturer's specifications, prior to blocking Fc using a commercial blocker. The samples were evaluated in triplicate in the LSR II cytometer (BD Biosciences) and analyzed through the software FACSDiva version 6.1.3.

### Determination of the enzymatic activity of DPP4 by fluorometric assay

Monocyte-like THP-1 cells and THP1-M $\Phi$  were treated with the GR antagonist RU486 before the stimulation of Dex for 24 h or with Dex during the first 3 h before adding two concentrations of the specific inhibitors of DPP4, sitagliptin and linagliptin. The cells were collected and lysed with lysis solution according to the manufacturer's instructions using the commercial kit DPP4 Activity Assay (Sigma–Aldrich). The results were plotted as pmol/ml/min (microunits/ml), where 1 unit of DPP4 is the amount of enzyme that hydrolyzes the DPP4 substrate to produce 1.0  $\mu$ mol of AMC/min at 37 °C.

### In silico analysis of GREs in the human DPP4 gene

Analysis in silico using the JASPAR software database revealed the presence of putative GREs in the promoter region. These GREs were mapped and analyzed by multiple alignments against the consensus sequence using the STAMP software, demonstrating a likelihood of GR binding in those regions of the DNA. According to this, primer probes flanking each of the GREs found in the promoter region of DPP4 were used for ChIP-qPCR and FAIRE analysis.

### ChIP-qPCR and FAIRE analysis

Monocyte-like THP-1 cells and THP1-M $\Phi$  seeded at a density of  $1 \times 10^6$  cells/ml stimulated with or without 100 nM Dex for 2 h were collected and evaluated by ChIP using the EZ-Magna ChIP™ A/G chromatin immunoprecipitation kit with immunomagnetic beads (EMD Millipore). For this, centrifuged and pelleted cells were cross-linked using 1% formaldehyde for 10 min at room temperature followed by quenching of the reaction with  $1 \times$  glycine for 5 min and then lysed and homogenized with a Dounce homogenizer for isolation of the nuclear fraction in a solution containing cComplete™ protease inhibitor mixture (Sigma–Aldrich). The nuclear fraction isolated was sonicated in a Bioractor® with a controlled-temperature high-pressure cooling system (Diagenode, Sparta, NJ). A fraction of the fragmented chromatin was used to evaluate the quality of chromatin through agarose gel electrophoresis. DNA fragments sized between 0.2 and 0.5 kb were immunoprecipitated using 3  $\mu$ g of anti-GR mAb (Cell Signaling) or the same concentration of anti-IgG as isotype control (EMD-Millipore). Subsequently, the immunocomplexes were isolated using magnetic beads of protein A/G-agarose; washed with solutions of low and high concentration of salts, LiCl solution, and TE buffer; and treated with RNase, proteinase K, and temperature to dissociate them for recovery and elution of the DNA. Aliquots of each DNA sample recovered were purified using columns, analyzed by quantitative PCR, using primers-probes flanking the two GREs: GRE -4,200/-4,185 (forward, 5'-CCTAGTGGAGCTGTGA-GAAGA-3'; probe, 5'-TCCAGTTACACGGAACAAGCTG-TCC-3'; reverse, 5'-CAGGCTGGCGTTGAGTATATG-3') and GRE -1,782/-1,767 (forward, 5'-GCACAGGGTGTGA-AGATATTTG-3'; probe, 5'-TGCCCTCCAGAGAACAAAT-TGACCT-3'; reverse, 5'-GAGGCTGGCTGACATCTAC-3'). The *Ct* values of each of the samples analyzed in triplicate were compared with respect to the initial input and normalized to the IgG isotype values and expressed as the -fold enrichment of

the stimulated condition compared with the control. Additionally, GRE located in the promoter of the *GILZ* gene was used as a positive control. FAIRE analysis was performed according to Simon *et al.* (51) using the same set of primers-probes previously analyzed for ChIP-qPCR.

**Experimental setup for mouse peritoneal macrophages and bone marrow–derived macrophages**

Peritoneal macrophages (PM) and BMDMs were isolated from 8–12-week-old C57BL/6 mice by flushing the peritoneal cavity with 5 ml of ice-cold complete medium and flushing the femur and tibia with complete medium, respectively. The BMM were purified by negative selection using the EasySep™ mouse monocyte isolation kit (Stemcell Tech, Vancouver, Canada) and resuspended in complete medium supplemented with 100 ng/ml M-CSF (Miltenyi Biotec, Bergisch Gladbach, Germany). Cells at a density of  $5.0 \times 10^5$  cells/well were incubated for 6 days at 37 °C and 5% CO<sub>2</sub> with medium change every 3 days. The BMDM phenotype was analyzed by phase-contrast microscopy and confocal immunofluorescence using anti-CD68 antibody (Biolegend, San Diego, CA); by flow cytometry of the surface markers Ly6C-PerCP/Cy5.5, CD11b-FITC, F4/80-APC and DPP4-PE, as well as the M1 and M2 markers CD80-BV421 and CD206-PE/Cy7, respectively (Biolegend); and by the gene expression profile using qRT-PCR. For polarization to M1 and M2, BMDMs unpolarized (M0) were stimulated for 24 h with 10 ng/ml murine recombinant interferon- $\gamma$  (Miltenyi Biotec) and 50 ng/ml lipopolysaccharide (Sigma) and with 10 ng/ml murine recombinant interleukin-4 (Miltenyi Biotec) to the M1 and M2, respectively, in 10% charcoal-stripped serum. For the experimental setup, M0, M1, and M2 macrophages were stimulated with 100 nM Dex for 6 h for the gene expression profile and until 24 h for protein analysis.

**Analysis of migratory capacity of monocyte-like THP-1 cells, THP-1–derived macrophages, peritoneal macrophages, and BMDMs unpolarized and polarized to M1 and M2**

Monocyte-like THP-1 cells, 6-day THP1-MO untransfected (mock) and transfected (NTC, GR siRNA and DPP4 siRNA), were treated with or without 100 nM Dex for 24 hours and then evaluated for their migratory properties. For some experiments, cells were preincubated with 10  $\mu$ M RU-486 for 1 hour prior to the addition of Dex. PM and BMDM (unpolarized and polarized to M1 and M2) were treated in the same manner as described above. Immediately after the stimulation, the supernatant was collected, and the cells were washed and detached with fresh and warmed 10 mM PBS-EDTA, collected in serum-free medium (without chemoattractant molecules) or in the presence of DPP4 inhibitors, counted, and reseeded at a density of  $4 \times 10^5$  cells/ml in the insert of a QCM™ Chemotaxis 5- $\mu$ m 24-well migration assay (with a 5- $\mu$ m pore size for monocyte/macrophage movement) (EMDMillipore, Burlington, MA), and medium with 10% FBS or 100 ng/ml CXCL12/SDF-1a (human or mouse) as a chemoattractant in the lower chamber. After 6 and 24 h, the migratory cells that adhered to the lower surface of the insert in the chamber were detached, lysed, and quantitated by the incorporation of a fluorescent probe CyQUANT® GR dye in a plate reader, according to the man-

ufacturer’s instructions. Each migration assay was repeated three times. The percentage of cells migrated was calculated in relation to unstimulated or untransfected conditions.

**Immunofluorescence staining**

M0, M1, and M2 macrophages were grown in glass-bottom culture dishes (MatTek Corp.). Then cells were washed with warm PBS, fixed with warm 4% paraformaldehyde for 20 min at room temperature, and permeabilized in PBS containing 2% BSA and 0.1% Triton X-100 for 30 min at room temperature. Cells were then blocked for 1 h with PBS containing 5% goat serum and 0.1% Triton X-100 at room temperature prior to incubation of the specimens at 4 °C overnight with anti-CD68 (Biolegend, San Diego, CA) antibody. The following morning, samples were washed with 1 $\times$  PBS containing 0.1% Tween and incubated with the secondary antibody goat anti-rat AF594 for 1 h at room temperature. Samples were then washed, air-dried, and mounted with ProLong gold antifade mountant with 4’,6-diamidino-2-phenylindole (Thermo Scientific). A Zeiss laser-scanning confocal microscope (LSM 880; Carl Zeiss) was used to analyze CD68 expression.

**Statistical analysis**

GraphPad Prism version 7.0 was used to analyze the data. To determine the statistical significance of the results, the two-tailed unpaired Student’s *t* test and one- or two-way ANOVA statistical test were performed with the ad hoc post-test according to the distribution of the data. Those comparisons whose value was *p* < 0.05 were considered statistically significant. In all of the experiments, the samples were analyzed in duplicate, and each experiment was performed at least three times independently.

---

*Author contributions*—D. D.-J., M. A. H., and J. A. C. conceptualization; D. D.-J. and J. A. C. data curation; D. D.-J. formal analysis; D. D.-J., M. G. P., J. T. B., and J. A. C. investigation; D. D.-J., M. G. P., J. T. B., and J. A. C. methodology; D. D.-J. and J. A. C. writing-original draft; D. D.-J., M. G. P., J. T. B., M. A. H., and J. A. C. writing-review and editing; M. A. H. and J. A. C. supervision; J. A. C. resources; J. A. C. funding acquisition.

---

*Acknowledgments*—We thank Carl Bortner and Maria Sifre of the Flow Cytometry core (NIEHS, National Institutes of Health (NIH)) for assistance with flow cytometry analysis and also Kevin Gerrish, Rickie Fanin, and Liwen Liu of the Molecular Genomics core (NIEHS, NIH) for assistance with microarray data. The figures were created with BioRender.

**References**

1. Cohen, D. M., and Steger, D. J. (2017) Nuclear receptor function through genomics: lessons from the glucocorticoid receptor. *Trends Endocrinol. Metab.* **28**, 531–540 [CrossRef Medline](#)
2. Necela, B. M., and Cidlowski, J. A. (2004) A single amino acid change in the first zinc finger of the DNA binding domain of the glucocorticoid receptor regulates differential promoter selectivity. *J. Biol. Chem.* **279**, 39279–39288 [CrossRef Medline](#)
3. Koenen, M., Culemann, S., Vettorazzi, S., Caratti, G., Frappart, L., Baum, W., Krönke, G., Baschant, U., and Tuckermann, J. P. (2018) Glucocorticoid receptor in stromal cells is essential for glucocorticoid-mediated sup-

## Glucocorticoids mobilize macrophages via DPP4

- pression of inflammation in arthritis. *Ann. Rheum. Dis.* **77**, 1610–1618 [CrossRef Medline](#)
- Guo, B., Huang, X., Cooper, S., and Broxmeyer, H. E. (2017) Glucocorticoid hormone-induced chromatin remodeling enhances human hematopoietic stem cell homing and engraftment. *Nat. Med.* **23**, 424–428 [CrossRef Medline](#)
  - de Lange, P., Segeren, C. M., Koper, J. W., Wiemer, E., Sonneveld, P., Brinkmann, A. O., White, A., Brogan, I. J., de Jong, F. H., and Lamberts, S. W. (2001) Expression in hematological malignancies of a glucocorticoid receptor splice variant that augments glucocorticoid receptor-mediated effects in transfected cells. *Cancer Res.* **61**, 3937–3941 [Medline](#)
  - Lannan, E. A., Gallihier-Beckley, A. J., Scoltock, A. B., and Cidlowski, J. A. (2012) Proinflammatory actions of glucocorticoids: glucocorticoids and TNF $\alpha$  coregulate gene expression *in vitro* and *in vivo*. *Endocrinology* **153**, 3701–3712 [CrossRef Medline](#)
  - Desmet, S. J., and De Bosscher, K. (2017) Glucocorticoid receptors: finding the middle ground. *J. Clin. Invest.* **127**, 1136–1145 [CrossRef Medline](#)
  - Hermoso, M. A., Matsuguchi, T., Smoak, K., and Cidlowski, J. A. (2004) Glucocorticoids and tumor necrosis factor  $\alpha$  cooperatively regulate toll-like receptor 2 gene expression. *Mol. Cell Biol.* **24**, 4743–4756 [CrossRef Medline](#)
  - Busillo, J. M., Azzam, K. M., and Cidlowski, J. A. (2011) Glucocorticoids sensitize the innate immune system through regulation of the NLRP3 inflammasome. *J. Biol. Chem.* **286**, 38703–38713 [CrossRef Medline](#)
  - Frank, M. G., Miguel, Z. D., Watkins, L. R., and Maier, S. F. (2010) Prior exposure to glucocorticoids sensitizes the neuroinflammatory and peripheral inflammatory responses to *E. coli* lipopolysaccharide. *Brain Behav. Immun.* **24**, 19–30 [CrossRef Medline](#)
  - van de Garde, M. D., Martinez, F. O., Melgert, B. N., Hylkema, M. N., Jonkers, R. E., and Hamann, J. (2014) Chronic exposure to glucocorticoids shapes gene expression and modulates innate and adaptive activation pathways in macrophages with distinct changes in leukocyte attraction. *J. Immunol.* **192**, 1196–1208 [CrossRef Medline](#)
  - Murray, P. J., and Wynn, T. A. (2011) Protective and pathogenic functions of macrophage subsets. *Nat. Rev. Immunol.* **11**, 723–737 [CrossRef Medline](#)
  - Ishiguro, Y., Ohkawara, T., Sakuraba, H., Yamagata, K., Hiraga, H., Yamaguchi, S., Fukuda, S., Munakata, A., Nakane, A., and Nishihira, J. (2006) Macrophage migration inhibitory factor has a proinflammatory activity via the p38 pathway in glucocorticoid-resistant ulcerative colitis. *Clin. Immunol.* **120**, 335–341 [CrossRef Medline](#)
  - Apostolopoulos, D., and Morand, E. F. (2017) It hasn't gone away: the problem of glucocorticoid use in lupus remains. *Rheumatology* **56**, i114–i122 [CrossRef Medline](#)
  - Ayoub, S., Hickey, M. J., and Morand, E. F. (2008) Mechanisms of disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis. *Nat. Clin. Pract. Rheumatol.* **4**, 98–105 [CrossRef Medline](#)
  - Martinez, F. O., Gordon, S., Locati, M., and Mantovani, A. (2006) Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. *J. Immunol.* **177**, 7303–7311 [CrossRef Medline](#)
  - Ginhoux, F., Schultze, J. L., Murray, P. J., Ochando, J., and Biswas, S. K. (2016) New insights into the multidimensional concept of macrophage ontogeny, activation and function. *Nat. Immunol.* **17**, 34–40 [CrossRef Medline](#)
  - Bain, C. C., Bravo-Blas, A., Scott, C. L., Perdiguero, E. G., Geissmann, F., Henri, S., Malissen, B., Osborne, L. C., Artis, D., and Mowat, A. M. (2014) Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. *Nat. Immunol.* **15**, 929–937 [CrossRef Medline](#)
  - Jakubzick, C., Gautier, E. L., Gibbings, S. L., Sojka, D. K., Schlitzer, A., Johnson, T. E., Ivanov, S., Duan, Q., Bala, S., Condon, T., van Rooijen, N., Grainger, J. R., Belkaid, Y., Ma'ayan, A., Riches, D. W., *et al.* (2013) Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. *Immunity* **39**, 599–610 [CrossRef Medline](#)
  - Liao, X., Shen, Y., Zhang, R., Sugi, K., Vasudevan, N. T., Alaiti, M. A., Sweet, D. R., Zhou, L., Qing, Y., Gerson, S. L., Fu, C., Wynshaw-Boris, A., Hu, R., Schwartz, M. A., Fujioka, H., *et al.* (2018) Distinct roles of resident and nonresident macrophages in nonischemic cardiomyopathy. *Proc. Natl. Acad. Sci. U.S.A.* **115**, E4661–E4669 [CrossRef Medline](#)
  - Shah, Z., Kampfrath, T., Deiluiis, J. A., Zhong, J., Pineda, C., Ying, Z., Xu, X., Lu, B., Moffatt-Bruce, S., Durairaj, R., Sun, Q., Mihai, G., Maisey, A., and Rajagopalan, S. (2011) Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. *Circulation* **124**, 2338–2349 [CrossRef Medline](#)
  - Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., Ring, A. M., Connolly, A. J., and Weissman, I. L. (2017) PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. *Nature* **545**, 495–499 [CrossRef Medline](#)
  - Cucak, H., Grunnet, L. G., and Rosendahl, A. (2014) Accumulation of M1-like macrophages in type 2 diabetic islets is followed by a systemic shift in macrophage polarization. *J. Leukoc. Biol.* **95**, 149–160 [CrossRef Medline](#)
  - Zhuge, F., Ni, Y., Nagashimada, M., Nagata, N., Xu, L., Mukaida, N., Kaneko, S., and Ota, T. (2016) DPP-4 inhibition by linagliptin attenuates obesity-related inflammation and insulin resistance by regulating M1/M2 macrophage polarization. *Diabetes* **65**, 2966–2979 [CrossRef Medline](#)
  - Bingle, L., Brown, N. J., and Lewis, C. E. (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. *J. Pathol.* **196**, 254–265 [CrossRef Medline](#)
  - Vogel, D. Y., Heijnen, P. D., Breur, M., de Vries, H. E., Tool, A. T., Amor, S., and Dijkstra, C. D. (2014) Macrophages migrate in an activation-dependent manner to chemokines involved in neuroinflammation. *J. Neuroinflammation* **11**, 23 [CrossRef Medline](#)
  - Angsana, J., Chen, J., Liu, L., Haller, C. A., and Chaikof, E. L. (2016) Efferocytosis as a regulator of macrophage chemokine receptor expression and polarization. *Eur. J. Immunol.* **46**, 1592–1599 [CrossRef Medline](#)
  - Heideveld, E., Hampton-O'Neil, L. A., Cross, S. J., van Alphen, F. P. J., van den Biggelaar, M., Toye, A. M., and van den Akker, E. (2018) Glucocorticoids induce differentiation of monocytes towards macrophages that share functional and phenotypical aspects with erythroid island macrophages. *Haematologica* **103**, 395–405 [CrossRef Medline](#)
  - Zhong, J., Maisey, A., Davis, S. N., and Rajagopalan, S. (2015) DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. *Circ. Res.* **116**, 1491–1504 [CrossRef Medline](#)
  - Röhrborn, D., Wronkowitz, N., and Eckel, J. (2015) DPP4 in diabetes. *Front. Immunol.* **6**, 386 [CrossRef Medline](#)
  - Röhrborn, D., Brückner, J., Sell, H., and Eckel, J. (2016) Reduced DPP4 activity improves insulin signaling in primary human adipocytes. *Biochem. Biophys. Res. Commun.* **471**, 348–354 [CrossRef Medline](#)
  - Zhong, J., Rao, X., Deiluiis, J., Braunstein, Z., Narula, V., Hazey, J., Mikami, D., Needleman, B., Satoskar, A. R., and Rajagopalan, S. (2013) A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation. *Diabetes* **62**, 149–157 [CrossRef Medline](#)
  - Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., and Sitagliptin 036 Study Group (2007) Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. *Diabetes Care* **30**, 1979–1987 [CrossRef Medline](#)
  - Takahashi, H., Nishimura, R., Tsujino, D., and Utsunomiya, K. (2019) Which is better, high-dose metformin monotherapy or low-dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low-dose metformin monotherapy? A randomized, cross-over, continuous glucose monitoring-based pilot study. *J. Diabetes Investig.* **10**, 714–722 [CrossRef Medline](#)
  - Vilbøll, T., Ekholm, E., Johnsson, E., Dronamraju, N., Jabbour, S., and Lind, M. (2019) Dapagliflozin plus saxagliptin add-on therapy compared with insulin in patients with type 2 diabetes poorly controlled by metformin with or without sulfonylurea therapy: a randomized clinical trial. *Diabetes Care* **42**, 1464–1472 [CrossRef Medline](#)
  - van Genugten, R. E., van Raalte, D. H., Muskiet, M. H., Heymans, M. W., Pouwels, P. J., Ouwens, D. M., Mari, A., and Diamant, M. (2014) Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glu-



- corticoids in men with the metabolic syndrome? A randomized controlled trial. *Eur. J. Endocrinol.* **170**, 429–439 [CrossRef Medline](#)
37. Yata, Y., Hosojima, M., Kabasawa, H., Ishikawa, T., Kaseda, R., Iino, N., Suzuki, Y., Saito, A., and Narita, I. (2017) The assessment of the efficacy of dipeptidyl peptidase-4 inhibitors in patients with glucocorticoid-induced diabetes by continuous glucose monitoring. *Intern. Med.* **56**, 2555–2562 [CrossRef Medline](#)
  38. Jewell, C. M., Katen, K. S., Barber, L. M., Cannon, C., Garantziotis, S., and Cidlowski, J. A. (2016) Healthy glucocorticoid receptor N363S carriers dysregulate gene expression associated with metabolic syndrome. *Am. J. Physiol. Endocrinol. Metab.* **311**, E741–E748 [CrossRef Medline](#)
  39. Busillo, J. M., and Cidlowski, J. A. (2013) The five Rs of glucocorticoid action during inflammation: ready, reinforce, repress, resolve, and restore. *Trends Endocrinol. Metab.* **24**, 109–119 [CrossRef Medline](#)
  40. Cain, D. W., and Cidlowski, J. A. (2017) Immune regulation by glucocorticoids. *Nat. Rev. Immunol.* **17**, 233–247 [CrossRef Medline](#)
  41. Herrera, C., Morimoto, C., Blanco, J., Mallol, J., Arenzana, F., Lluís, C., and Franco, R. (2001) Comodulation of CXCR4 and CD26 in human lymphocytes. *J. Biol. Chem.* **276**, 19532–19539 [CrossRef Medline](#)
  42. Crowley, M. J., Williams, J. W., Jr, Kosinski, A. S., D'Alessio, D. A., and Buse, J. B. (2017) Metformin use may moderate the effect of DPP-4 inhibitors on cardiovascular outcomes. *Diabetes Care* **40**, 1787–1789 [CrossRef Medline](#)
  43. Yen, F. S., Chiang, J. H., Pan, C. W., Lin, B. J., Wei, J. C., and Hsu, C. C. (2018) Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy. *Diabetes Res. Clin. Pract.* **140**, 279–287 [CrossRef Medline](#)
  44. Ou, S. M., Chen, H. T., Kuo, S. C., Chen, T. J., Shih, C. J., and Chen, Y. T. (2017) Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure. *Heart* **103**, 414–420 [CrossRef Medline](#)
  45. Zhong, J., and Rajagopalan, S. (2015) Dipeptidyl peptidase-4 regulation of SDF-1/CXCR4 axis: implications for cardiovascular disease. *Front. Immunol.* **6**, 477 [CrossRef Medline](#)
  46. Blauenfeldt, T., Petrone, L., Del Nonno, F., Baiocchi, A., Falasca, L., Chiacchio, T., Bondet, V., Vanini, V., Palmieri, F., Galluccio, G., Casrouge, A., Eugen-Olsen, J., Albert, M. L., Goletti, D., Duffy, D., and Ruhwald, M. (2018) Interplay of DPP4 and IP-10 as a potential mechanism for cell recruitment to tuberculosis lesions. *Front. Immunol.* **9**, 1456 [CrossRef Medline](#)
  47. Broxmeyer, H. E., Capitano, M., Campbell, T. B., Hangoc, G., and Cooper, S. (2016) Modulation of hematopoietic chemokine effects *in vitro* and *in vivo* by DPP-4/CD26. *Stem Cells Dev.* **25**, 575–585 [CrossRef Medline](#)
  48. Hiromura, M., Nohtomi, K., Mori, Y., Kataoka, H., Sugano, M., Ohnuma, K., Kuwata, H., and Hirano, T. (2018) Caveolin-1, a binding protein of CD26, is essential for the anti-inflammatory effects of dipeptidyl peptidase-4 inhibitors on human and mouse macrophages. *Biochem. Biophys. Res. Commun.* **495**, 223–229 [CrossRef Medline](#)
  49. Díaz, J., Mendoza, P., Ortiz, R., Díaz, N., Leyton, L., Stupack, D., Quest, A. F., and Torres, V. A. (2014) Rab5 is required in metastatic cancer cells for Caveolin-1-enhanced Rac1 activation, migration and invasion. *J. Cell Sci.* **127**, 2401–2406 [CrossRef Medline](#)
  50. Grande-García, A., Echarri, A., de Rooij, J., Alderson, N. B., Waterman-Storer, C. M., Valdivielso, J. M., and del Pozo, M. A. (2007) Caveolin-1 regulates cell polarization and directional migration through Src kinase and Rho GTPases. *J. Cell Biol.* **177**, 683–694 [CrossRef Medline](#)
  51. Simon, J. M., Giresi, P. G., Davis, I. J., and Lieb, J. D. (2013) A detailed protocol for formaldehyde-assisted isolation of regulatory elements (FAIRE). *Curr. Protoc. Mol. Biol.*, Chapter 21, Unit 21.26 [CrossRef Medline](#)